Resource Center
Explore our library of helpful resources and scientific content on Misetionamide.
Filter by Resource Type
- Press Releases
- Posters
- Publications
- Brochures
- Videos
- Events
Press Release – June 13, 2025
Panavance Therapeutics Announces Promising Misetionamide (GP-2250) Phase 1 Clinical Trial Interim Findings in Pancreatic Cancer at BIO 2025
Read Release
poster
Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors
Read More
Press Release – November 19, 2024
Panavance Announces New Discovery that Misetionamide Directly Inhibits Oncogenic Transcription Factor c-MYC
Read Release
Press Release – October 9, 2024
Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at 2024 Visceral Medicine Congress
Read Release
Press Release – August 14, 2024
Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine
Read Release
publication
Publication Summary – Misetionamide (GP-2250)
A summary of all publications with links to full document
Read More
publication
Mechanisms and rational combinations with GP-2250, novel oxathiazine derivative in ovarian cancer.
Mark Kim, Deanna Glassman, Katelyn F Handley, Adrian Lankenau ahumada, Emine Bayraktar, Nicholas B. Jennings, Robiya Joseph, Robert L. Coleman and Anil K. Sood.
Read More
publication
Antineoplastic activity of GP-2250 in-vitro and in mouse xenograft models
R. Duane Sofia, Kathryn M. Martin and James C. Costin
Read More
publication
Increasing the cytotoxic effectivity of 5FU, Irinotecan and Oxaliplatin on pancreatic cancer cells through combination with the novel anticancer agent GP-2250 in vitro
I.Peters; B. Majchrzak-Stiller ; M. Buchholz ; P. Höhn ; W. Uhl ; C. Braumann ; J. Strotmann
Read More
Press Release – February 1, 2024
Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)
Read Release
publication
GP- 2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP- Kinase and impairs the NF- kB pathway in pancreatic cancer cells
Britta Majchrzak- Stiller, Marie Buchholz, Ilka Peters, Daniel Waschestjuk, Johanna Strotmann, Philipp Höhn, Stephan Hahn, Chris Braumann, Waldemar Uhl, Thomas Müller, Hanns Möhler
Read More
publication
Oxathiazinane Derivatives Display Both Anticancer and Antibacterial Activity: A Structure Activity Study
Read More
publication
An In Vitro Pilot Study Investigating the Antineoplastic Effects of GP-2250 on Cutaneous Squamous Cell Carcinoma Cell Lines: Preliminary Results
Read More
Press Release – November 21, 2023
International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma
Read Release
publication
The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results
Thilo Gambichler, Britta Majchrzak-Stiller, Ilka Peters, Jürgen C Becker, Johanna Strotmann, Nessr Abu Rached, Thomas Müller, Waldemar Uhl 2, Marie Buchholz, Chris Braumann
Read More
publication
Mechanisms and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer
American Association for Cancer Research (AACR) Annual Meeting 2023
Read More
publication
In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes
Thilo Gambichler , Friederike Harnischfeger , Marina Skrygan , Britta Majchrzak-Stiller , Marie Buchholz , Thomas Müller and Chris Braumann
Read More
Press Release – September 12, 2023
Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer
Read Release
event
Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Thursday, July 13th at 2:00 PM ET
Read More
Press Release – July 5, 2023
Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series
Read Release
Press Release – June 29, 2023
Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)
Read Release
Press Release – May 24, 2023
Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention
Read Release
Press Release – April 17, 2023
Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer
Read Release
Press Release – April 12, 2023
Panavance Therapeutics to Present at the BioNJ Annual BioPartnering Conference
Read Release
Press Release – March 20, 2023
Panavance Therapeutics Announces Acceptance of Abstract to be Presented at
the American Association for Cancer Research (AACR) Annual Meeting 2023
Read Release
event
Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Wednesday, January 18th at 1:00 PM ET
Read More
Press Release – January 5, 2023
Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
Read Release
event
Panavance Leadership Team participation in the Virtual Investor Innovations in Oncology Event
Greg Bosch, Chairman and CEO of Panavance Therapeutics along with other members of the Panavance Leadership Team participated in the Virtual Investor Innovations in Oncology Spotlight Event. As part of the virtual roundtable event, the Company discussed its lead program, GP-2250, a tumor cell selective and broadly active small molecule with a unique mechanism of action designed to disrupt energy metabolism, resulting in cancer cell death.
Read More
Press Release – December 5, 2022
Panavance Therapeutics to Participate at the Virtual Investor Innovations in Oncology Spotlight Event
Read Release
Press Release – November 14, 2022
Panavance Therapeutics to Present at the Pharma Partnering US Summit 2022
Read Release
Press Release – August 8, 2022
Panavance Therapeutics Announces Publication of Promising Preclinical Data Evaluating GP-2250 for the Treatment of Malignant Peritoneal Mesothelioma
Read Release
Press Release – June 28, 2022
Panavance Therapeutics Announces Orphan Drug Designation for GP-2250 for the Treatment of Pancreatic Cancer
Read Release
publication
Substance GP-2250 as a new therapeutic agent for malignant peritoneal mesothelioma – a 3-D in vitro study
Read More
publication
A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma.
Read More
publication
New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo
Read More
Press Release – June 9, 2022
Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Pancreatic Neuroendocrine Carcinoma
Read Release
video
Mechanism of Action Explainer Video
While cancer therapies are becoming increasingly specific to tumor and mutation type, a tumor and mutation agnostic yet targeted agent is of high therapeutic utility. Learn about GP-2250’s unique mechanism of action, which kills cancer cells by disrupting their energy metabolism.
Watch Video
brochure
New hope begins with novel science.
Panavance’s purpose is to give every patient the best possible chance to live a healthy and cancer-free life.
Read More
publication
Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. Journal of Clinical Oncology Vol. 28, No. 15-suppl. May 2020
Read More
Press Release – January 19, 2022
Panavance Announces Abstract and Poster at ASCO Gastrointestinal Cancers Symposium, Providing an Update on the Status of GP-2250 Clinical Trial in Pancreatic Cancer Patients
Read Release